Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer

– Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities

– Company recently initiated clinical trial of novel digital therapeutic for childhood myopia

Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the Company.

Mark Wuttke brings more than two decades of healthcare business expertise, in particular, comprehensive experience in the development and commercialization of ophthalmology products at Novartis, a global leader in eye health. He also has a strong track record in corporate strategy and branding. Read more…

Neonatal Diagnostics Company InfanDx AG Completes Two-Year Patient Follow-Up in BANON Study

— Clinical data curation and evaluation ongoing

— Follow-up rate of 77% fully meets expectations (70-80%)

— Final HIE biomarker panel validation data expected by end of Q3-2022


InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, announced at an investigator meeting during the recent 48th Annual Meeting of the German Society for Neonatology and Pediatric Intensive Medicine that the clinical 2-year follow-up of patients originally enrolled in the BANON study was formally completed. The study is designed to validate novel diagnostic biomarkers of Hypoxic-Ischemic Encephalopathy (HIE).

Read more…

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

– Novel ion channel blocker designed to combine high efficacy and durable response while maintaining full immune system functionality

San Diego, CA, USA, and Munich, Germany – May 9, 2022 – selectION, Inc., a biopharmaceutical company developing novel peptide therapies for the treatment of T cell mediated autoimmune diseases and rare lymphomas, today announced that Germany´s regulatory agency has authorized the Company’s clinical trial application for a Phase 1b trial evaluating the safety and efficacy of selectION´s clinical candidate, si-544, in patients diagnosed with mild to severe atopic dermatitis.

Read more…

Omnix Medical Starts Phase I Clinical Trial of Novel Anti-Infective; First Healthy Volunteers Dosed

– New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives

Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since March 28, 2022, six healthy volunteers have been administered the novel antimicrobial, which is based on a naturally occuring mechanism of action (MoA) leading to a targeted, effective destruction of the cell membrane of pathogens. The trial is being conducted in Groningen, The Netherlands. OMN6 is being evaluated in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of single and repeat IV infusion of the compound in healthy subjects. Results are expected by Q4, 2022.

Read more…

1 2 170